Last reviewed · How we verify
NCT06767124
Supplementing Neuro-Energy to Aid Cognition
NA trial testing Ketogenic Supplement in Alzheimer Disease and Related Dementias (ADRD) in 17 participants. Not yet recruiting.
29 February 2028
Quick facts
| Lead sponsor | University of Pennsylvania |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 17 |
| Start date | 1 May 2026 |
| Primary completion | 29 February 2028 |
| Estimated completion | 31 March 2028 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Ketogenic Supplement
- Placebo Drink — full drug profile →
Conditions studied
- Alzheimer Disease and Related Dementias (ADRD) — all drugs for Alzheimer Disease and Related Dementias (ADRD) →
Sponsor
University of Pennsylvania
Who can join
21 and older, any sex, with Alzheimer Disease and Related Dementias (ADRD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It is projected that by 2030, one in every five Americans will be of retirement age, and this demographic shift is expected to result in more people suffering from dementia. A key feature of the brain is its need for a constant supply of glucose and oxygen to meet the high energy costs of mental activity. This study aims to develop clinically practical, noninvasive imaging methods based on combined positron emission tomography and magnetic resonance imaging to assess brain energy in order to better understand how this critical component of brain health is impacted by aging.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Energetic Collapse of the Alzheimer's Brain: Metabolic Inflexibility Across Cells and Networks.
Constantino NJ, Ashley CC, Macauley SL. · · 2025 · cited 2× · PMID 41231438 · DOI 10.1111/jnc.70294
Verify or expand the search:
- PubMed search for NCT06767124
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alzheimer Disease and Related Dementias (ADRD)
Currently open trials in the same condition.
- NCT07120347 — Remote Sensing for ADRD-Specific Activities Identification in Older Adults · NA · recruiting
- NCT06112860 — OTC Hearing Aid and MCI · NA · recruiting
- NCT06224205 — Digital Detection of Dementia (D Cubed) Studies: D3 · NA · recruiting
Other University of Pennsylvania trials
Trials by the same sponsor.
- NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
- NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
- NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
- NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
- NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06767124 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
- Last refreshed: 14 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06767124.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing